Table 6.

Overall survival by blast count in combined groups of MDS with erythroid hyperplasia, AEL, and AML-MRC with erythroid hyperplasia (205 patients total) and of MDS cases without erythroid hyperplasia (179 patients total)

	No. of patients in each group	Median overall survival, mo	Log-rank test for trend, P
Combined AEL and MDS/AML-MRC with erythroid hyperplasia cases, stratified by blasts as % of all cells			.71
Less than 5	30	13
5-9	47	8
10-14	45	9
15-19	42	11
More than 20	41	10
Combined AEL and MDS/AML-MRC with erythroid hyperplasia cases, stratified by blasts as a % of nonerythroid cells			.33
Less than 10	20	14
10-19	20	17
20-29	47	6
More than 30	118	10
MDS cases without erythroid hyperplasia, stratified by blasts as % of all cells			< .001
Less than 5	115	Not reached
5-9	44	16
10-19	20	11